Hualan Biological Engineering Inc. (002007.SZ)
- Previous Close
16.34 - Open
16.14 - Bid 16.39 x --
- Ask 16.40 x --
- Day's Range
16.28 - 16.52 - 52 Week Range
13.72 - 19.70 - Volume
7,664,420 - Avg. Volume
12,527,576 - Market Cap (intraday)
29.992B - Beta (5Y Monthly) 0.65
- PE Ratio (TTM)
26.45 - EPS (TTM)
0.62 - Earnings Date Apr 28, 2025
- Forward Dividend & Yield 0.30 (1.84%)
- Ex-Dividend Date Jun 14, 2024
- 1y Target Est
19.00
Hualan Biological Engineering Inc., a biopharmaceutical company, researches, develops, produces, and commercializes blood products, vaccines, and recombinant proteins in China and internationally. The company offers blood products under the Hualan brand comprising human albumin, intravenous human immunoglobulin, human immunoglobulin, tetanus human immunoglobulin, hepatitis B human immunoglobulin, rabies immunoglobulin, human prothrombin complex, human coagulation factor VIII, human fibrinogen, freeze-dried human fibrin glue for surgery, and human fibrin adhesives. It also provides vaccines consisting of quadrivalent and split influenza virus vaccines, influenza A (H1N1) split vaccines, ACYW135 group meningococcal polysaccharide vaccines, recombinant hepatitis B vaccines, group A and C meningococcal polysaccharide vaccines, freeze-dried human rabies vaccines, adsorbed tetanus vaccines, and multiple vaccine products; and biological products. In addition, the company is involved in plasma collection; poultry breeding for research and development; engineering technology research and experimental development; inspection and testing; biotechnology development; and medical services. Hualan Biological Engineering Inc. was founded in 1992 and is headquartered in Xinxiang City, the People's Republic of China.
www.hualanbio.comRecent News: 002007.SZ
View MorePerformance Overview: 002007.SZ
Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 002007.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 002007.SZ
View MoreValuation Measures
Market Cap
29.88B
Enterprise Value
27.32B
Trailing P/E
26.23
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.70
Price/Book (mrq)
2.45
Enterprise Value/Revenue
6.13
Enterprise Value/EBITDA
19.43
Financial Highlights
Profitability and Income Statement
Profit Margin
25.55%
Return on Assets (ttm)
4.72%
Return on Equity (ttm)
8.64%
Revenue (ttm)
4.46B
Net Income Avi to Common (ttm)
1.14B
Diluted EPS (ttm)
0.62
Balance Sheet and Cash Flow
Total Cash (mrq)
3.65B
Total Debt/Equity (mrq)
7.68%
Levered Free Cash Flow (ttm)
-596.66M